Abstract
Introduction
Th17 cells are a subset of T helper cells that play important roles in host defense and the pathogenesis of various human autoimmune and inflammatory diseases (Bettelli et al., 2007) . Th17 cells produce interleukin (IL)-17A, IL-17F, IL-22, and IL-21, of which IL-17A and IL-17F mediate many of the downstream pathological effects in these cells (Iwakura et al., 2011) . IL-17 acts in vitro and in vivo as a potent inflammatory cytokine. IL-17 has pleiotropic activities, one of which is to coordinate tissue inflammation by inducing tumor necrosis factor (TNF)-α, Il-1β, IL-6, IL-8, granulocyte colony-stimulating factor (G-CSF), and monocyte chemoattractant protein-1 (MCP-1), in various types of cells, which mediate tissue infiltration and tissue destruction (Fossiez et al., 1998; Kolls and Linden, 2004) . IL-17 also seems to play an important role in rheumatoid arthritis (RA) angiogenesis because of its ability to promote blood vessel growth (Pickens et al., 2010) . Furthermore, IL-17 is involved in the host defense mechanism against lung bacterial infection, because of reduced recruitment of neutrophils to the lungs in IL-17R -/-mice (Ye et al., 2001 ). Elevated IL-17 levels are found in serum and tissues of patients with various autoimmune diseases, including RA (Shahrara et al., 2008) , multiple sclerosis (Tzartos et al., 2008) , and systemic lupus erythematosus (Wong et al., 2000) . In a previous study, we showed that IL-17 protein and mRNA levels were high in the serum and synovial fluid of patients with RA, and that IL-17 was expressed in the synovium of patients with RA. In the absence of IL-17, mice are resistant to the development of collagen-induced arthritis (CIA) (Nakae et al., 2003a; Lubberts et al., 2004) , autoimmune encephalomyelitis (Komiyama et al., 2006) , autoimmune uveoretinitis (Zhang et al., 2009) , and other autoimmune diseases (Kikly et al., 2006) . In line with this observation, our group previously showed that IL-17 producing T cells are increased in RA patients and Th17 are key effector cell in driving autoimmunity (Kim et al., 2005; Cho et al., 2006a; Lee et al., 2009) .
Although Th1 cells had long been considered to be essential for driving autoimmune pathology, interferon (IFN)-γ does not appear to be a major driver of autoimmunity, as IFN-γ -/-mice are still susceptible to disease (Ferber et al., 1996; Chu et al., 2003) . Interestingly, mice deficient in ICOS ("inducible costimulator," a co-stimulatory molecule for T cells activation), are completely resistant to CIA and show a large deficit in IL-17 levels, although they produce normal levels of TNF-α and IFN-γ (Lubberts, 2008) . IL-23-deficient mice have no IL-17-producing CD4 + T cells, but the normal IFN-γ-producing Th1 cells are completely protected against the development of CIA (Murphy et al., 2003) . Additionally, IL-17 plays a key role in the induction of experimental arthritis, as shown in IL-1 receptor antagonist-deficient mice, which develop arthritis spontaneously due to excessive IL-1 signaling (Nakae et al., 2003b) . Consistent with this, IL-17 deficient mice are also resistant to CIA. These results point to a significant role for IL-17 in the immunopathology of various autoimmune diseases in mice.
Administration of type II collagen (CII) and complete Freund's adjuvant (CFA) to DBA/1J mice induces the development of inflammatory erosive arthritis. CIA mice expressing the H-2q major histocompatibility complex (MHC) allele develop inflammatory synovitis of the paws, with synoviocyte proliferation, pannus formation, bone erosion, and cartilage destruction, strikingly similar to RA in humans. IL-17 is a pivotal cytokine in RA and is related to the major pathogenic mechanism of developing CIA [11] . The CIA mouse model is useful for studying proinflammatory cytokines, such as IL-17, IL-1β, IL-6, and TNF-α, in T cells autoreactive to CII (Myers et al., 1997) .
In the present study, we generated allogeneic bone marrow chimeras of IL-17 deficiency in a DBA/1J background. This model may be useful to demonstrate the role of IL-17 in the induction of CIA. The aim of this study was to reveal the impact of IL-17 and its mechanism of action in the CIA model. Our results demonstrated that a deficiency in IL-17 signaling prevented CIA development. Using this system, we found that IL-17 signaling within the hematopoietic compartment promoted disease progression by regulating autoreactive T cell responses and proinflammatory cytokine levels. Moreover, IL-17 blockade not only increased functionally suppressive Tregs, which inhibit proliferation of pathogenic Th17 cells, but also inhibited bone destruction in the CIA murine model. We conclude that IL-17 is indispensable for CIA development and suggest the therapeutic potential of lL-17 blockade in human arthritis conditions.
Results

Establishing a bone marrow (BM) transplant CIA model
We examined the fractioned irradiation (600 cGy × 2 = 1200 cGy, 6-h interval) necessary to destroy BM in the animals. Irradiated DBA/1J recipient mice were injected with BM from C57BL/6 (WT) or IL-17 knock-out (KO) donors. As shown in Table 1 , DBA/1J recipient mice (WT or IL-17KO BM) exhibited complete and stable donor chimerism with the H-2Kb major histocompatibility complex allele in peripheral blood, spleen, lymph nodes, and bone marrow 12 weeks after transplantation (Table 1) . Reconstitution of donor-derived cells in peripheral blood, spleen, lymph node, and BM was observed at normal B6 levels. No difference in the lineage pattern of any cell was observed between the groups, indicating that the presence of a systemic inflammatory autoimmune disease does not hamper the induction of allogeneic donor chimerism (Table 2) . By irradiating DBA mice and rescuing them with IL17 -/-bone marrow, we created chimeric mice in which the majority of hematopoietically derived cells could no longer produce IL-17, whereas the control group (WT) produced IL-17 normally. No mice exhibited signs of clinical graft-versus-host disease (GVHD; data not shown).
33.7 ± 4.3 37.1 ± 4.2 27.3 ± 4.6 24.4 ± 4.5 60.7 ± 1.0 54.4 ± 0.9 5 ± 0.1 5.7 ± 0.2 22.6 ± 0.7 25.1 ± 2.1 19.1 ± 2.3 16.8 ± 2.3 34.6 ± 0.8 30.4 ± 0.6 4.3 ± 0.5 4.9 ± 0.1 11 ± 3.1 11.9 ± 1.4 8.9 ± 2.1 8.9 ± 1.8 27.2 ± 0.9 22.1 ± 1.6 3.3 ± 0.5 3.4 ± 0.3 37.6 ± 5.7 31.4 ± 2.3 39.6 ± 1.6 42.1 ± 5.0 16 ± 0.3 18.2 ± 2.0 11.1 ± 0.9 11.7 ± 1.4 5.1 ± 0.5 7.6 ± 2.6 6.6 ± 0.3 5.9 ± 0.4 5 ± 0.3 4.9 ± 0.3 1.7 ± 0.1 1.7 ± 0.1 Analyses of cell surface antigens on peripheral blood (PB), spleen cells (sp), draining lymph node cells (dLN) or Bone marrow cells (BM) in the B6 → DBA1J (20 weeks after BMT) or the IL-17Ko → DBA1J (20 weeks after BMT) mice were analyzed using an FACS. The results are expressed as the mean SD of 6 mice. Figure 1A , left) and incidence of clinical arthritis ( Figure 1A , right), indicating a strong therapeutic effect. WT BMT-CIA mice demonstrated destruction of the articular cartilage, bone synovial hyperplasia, and infiltration by inflammatory cells ( Figure 1C ). In contrast, IL-17 KO-BMT CIA mice demonstrated no swelling or destruction of the articular cartilage ( Figure 1C ). Serum samples were analyzed for anti-collagen specific antibodies and proinflammatory cytokine by ELISA. As shown in Figure 1C , the CII specific IgG1, IgG2a, and total IgG antibody levels were significantly lower in IL-17KO-BMT CIA mice as compared with WT-BMT CIA mice ( Figure 1B ). The serum levels of IL-6, IL-1β, and TNF-α decreased in IL-17KO BMT mice as compared with WT-BMT CIA mice ( Figure 1D ). Additionally, in immunohistochemical stain of the joints, IL-6, IL-1β, and TNF-α + cells was decreased in IL-17KO BMT mice ( Figure 1E ). These results suggest that IL-17 blockade regulated the systemic inflammatory and humoral immune responses to CII.
Regulation of the CII-specific response by IL-17KO-BMT in CIA mice
We examined the T cell response following CII-specific stimulation to determine whether the reduction in CIA in transplanted IL-17 KO-BMT CIA mice was simply due to a defective T cell response to CII. A significant decrease was observed in the T cell proliferative response to CII, as indicated by decreased 3 H thymidine uptake in IL-17KO-BMT CIA mice as compared with WT-BMT mice ( Figure  2A ). These results indicate that IL-17 blockade during CIA development effectively suppressed the systemic autoimmune response to CII. While Tregs are known to regulate the immune response, Th17 cells are associated with the development and progression of joint inflammation. Based on these data, we next investigated the change in the Treg/Th17 ratio linked to the CII-specific immune response. We found that the Treg/Th17 ratio increased profoundly in IL-17KO BMT mice as compared with the WT BMT group ( Figure 2B ). Because the IL-17 level in IL-17KO-BMT CIA mice decreased, the Treg/Th17 ratio increased relatively as compared with WT-BMT CIA mice. These results show that the IL-17 blockade in T cells shifted the Treg/Th17 balance toward Tregs. 
Analysis of the T helper cell population in IL-17KO-BMT in CIA mice
To investigate the change in T helper cells following IL-17 deficiency in CIA mice, we analyzed the levels of T helper (Th)-related cytokines and transcription factors in the CD4 + T cells of each group. The percentages of IL-10-producing CD4 + T cells and Tregs were higher in IL-17KO-BMT CIA mice as compared with WT-BMT CIA mice. However, the percentage of Th1 and Th2 cells was not significantly different between the groups ( Figure 3A) . Subsequently, we observed helper T cell cytokine patterns in the culture supernatants of each group. Following the anti-CD3 stimulus, the levels of IL-10 and TGF-β were higher in CD4 + T cells from IL-17KO-BMT CIA mice as compared with CD4 + T cells from WT-BMT CIA mice ( Figure 3B ). The production of IFN-γ and IL-4 was not significantly different among the groups. These findings are consistent with those of the previous FACS analysis. A similar pattern of differential T helper cell lineage-specific transcription factor expression was also observed in CD4 + T cells from IL-17KO-BMT CIA mice as compared with CD4 + T cells from WT-BMT CIA mice ( Figure 3C ). It is well -/-bone marrow (IL-17 -/-→ DBA) (n = 7 per group) 8 weeks after administration of the primary immunization. Spleen or dLN cells were cultured with type II collagen (CII) for 3 days. The proliferation response was measured by incorporation of 3 H-thymidine. Graph shows the mean ± SEM. (B) Type II collagen (CII) specific Treg/Th17 regulation in spleen and draining lymph nodes (dLNs) from both chimeric mice. At 8 weeks after primary immunization, the spleens and dLN obtained from mice in each group were incubated with 40 g/ml of type II collagen (CII) for 3 days. CII-specific FoxP3:IL-17 ratio between CD4 + T cells in the spleen and dLN. Bars show the mean ± SEM. *P ＜ 0.05 by Student's t-test. known that STAT3, a signal transduction molecule of inflammatory cytokines, plays a key role as a positive regulator of RoRrt and IL-17 expression. Our results also show that CD4 + T cells in IL-17-deficient BMT-CIA mice exhibited decreased phosphorylated-STAT3, Y705, and Y727 expression ( Figure  3D ). These results indicate that decreased STAT3 activity suppressed proinflammatory cytokine production.
Suppression of CII-reactive effector T cell proliferation by iTregs from IL-17KO-BMT in CIA mice
We compared the ability to drive Treg differentiation in CD4 + T cells isolated from WT BMT and IL-17 KO-BMT CIA mice in an in vitro Treg culture condition and then analyzed the suppressive capacity of the induced Tregs. As shown in Figure  4A , Foxp3 + Treg cells increased in the spleen (7.2 ± 0.3 versus 6.2 ± 0.2, P ＞ 0.01) and draining lymph nodes (75.8 ± 1.6 versus 70.4 ± 1.7, P ＞ 0.05) of IL-17 KO-BMT CIA mice as compared with WT BMT mice. Moreover, Treg differentiation in CD4 + T cells isolated from dLN of IL-17 KO BMT-CIA mice cultured under Th17 polarizing conditions was more evident than that in WT-BMT mice (42.93 ± 1 versus 32.9 ± 1.8, P ＞ 0.002). We performed an in vitro Treg suppressive assay to further study expanded Treg-mediated effector T suppression. CD4 + T cells from CIA mice cultured under Th17 conditions were mixed with iTregs from WT-BMT or IL-17 KO-BMT CIA mice. As shown in Figure 4B , iTregs from IL-17 KO-BMT CIA mice exhibited a stronger capacity than iTregs from WT-BMT CIA mice. We also investigated the effects of Tregs from IL-17-deficient mice on Th17 cell differentiation. Adding iTreg from IL-17 KO BMT CIA mice to CFSE-labeled IL-17-producing cells resulted in an inhibition of the proliferation of effector T cells producing IL-17( 3.4 ± 0.1 versus 6.4 ± 0.1, P ＞ 0.001), while favoring an increase in the frequency of Foxp + T cells ( 18.4 ± 0.5 versus 0.96 ± 0.1, P ＞ 0.001) ( Figure 4C ). These results showed that activated Tregs in IL-17-deficient mice could affect differentiation of effector T cells by regulating the Treg/Th17 balance.
Inhibition of osteoclastogenesis differentiation in IL-17 KO DBA chimeric mice
Decreased arthritis disease activity was associated with a reduction in bone erosion and synovial inflammation in joints. Our histology data showed IL-17 deficiency in CIA reduced bone erosion and cartilage destruction in the arthritic joints of the CIA mice. We investigated whether an in vivo IL-17 blockade would ameliorate joint erosion. TRAP staining was used to examine the potential inhibition of osteoclastic activity by IL-17 blockade during CIA development. As shown in Figures 5A and 5B, most TRAP + cells were observed at sites of bone erosion in WT-BMT CIA mice, whereas no staining was observed in CIA mice that received IL-17 -/-bone marrow.
We observed a significant decrease in mRNA expression of the osteoclast-related markers TRAP, RANK, NFATc1, MMP-9, integrin-β3, cathepsin K, and Oscar in BM and joint cells from IL-17 KO-BMT CIA mice as compared with WT-BMT CIA mice ( Figure 5B ). Interestingly, we also observed a lower level of the osteoblast-associated gene, RUNX, and osteocalcin expression increased more in BM and joint cells from IL-17 KO BMT-CIA mice, compared with that in BM and joint cells from WT-BMT CIA mice. These data suggest that IL-17 deficiency induced a decrease in osteoclast activity and gene expression involved in bone mass regulation.
Discussion
Our results showed that IL-17 contributed to the pathogenesis of inflammatory arthritis. DBA/1J background mice, which were repopulated with transplanted BM from IL 17 deficient mice in our animal model, may be comparable with the population of cells arising from BM in patients with RA after IL-17 blockade therapy. CIA mice that received IL-17 -/-BM had decreased autoreactive inflammatory cell recruitment proliferation, cytokine production, and reduced joint inflammation. Additionally, IL-17 -/-DBA chimeric mice showed increased IL-10 and TGF-β production by CD4 + T cells and functional Treg cells. Thus, IL-17 blockade may provide a potential target for the therapeutic treatment of autoimmune arthritis.
Several lines of evidence suggest that Th17 cells are important in the pathogenesis of experimentally induced autoimmune arthritis (Lubberts, 2010) . IL-17 is expressed in the synovium of patients with RA (Chabaud et al., 1999) and in CIA mice (Lubberts et al., 2001) . CIA severity is reduced in IL-17-deficient mice (Nakae et al., 2003a) and mice administered neutralizing IL-17 antibodies (Lubberts et al., 2004) . We identified the function of IL-17 using allogeneic BMT.
Allogeneic BMT is a potentially curative therapy for various hematopoietic malignancies and immunological disease, such as idiopathic thrombocytopenic purpura in (NZW × BXSB) F1 mice, non-insulin-dependent diabetes mellitus in KK-Ay mice, and autoimmune diseases in MRL/MP-lpr/lpr mice (Ikehara et al., 1985; van den Brink and Burakoff, 2002) . Our group previously demonstrated that allogeneic mixed chimerism by BMT has the potential to correct established chronic inflammatory arthritis in the IL-1Ra
-/-mouse model of RA (Cho et al., 2006b) . A case of successful treatment of catastrophic antiphospholipid syndrome with autologous BMT has been reported. However, BMT has not been a safe option as compared with conventional immunosuppressive treatment to date. Several problems must be solved before allogeneic BMT becomes widely applied to autoimmune diseases. In addition to being a therapeutic method, BMT is a good method for identifying the function of specific genes in specific strains of mice without using KO mice. CIA mice are a rodent model of human RA. Mice with a H-2q (DBA/1J) background are highly susceptible to disease, whereas mice with a H-2b (C57BL/6) background are resistant to disease induction (Wooley et al., 1981) . DBA/1J mice are suitable for CIA pathogenesis research, such as measuring antigen-specific T and B cell responses (Seki et al., 1988; Holmdahl et al., 1990) . Thus, we transplanted BM from B6 background WT or IL-17 KO mice into DBA/1J mice. At 4 weeks after the BMT, DBA/1J mice transplanted with WT or IL-17 KO mice BM had CIA. Three weeks after the induction of CIA, WT-BMT mice developed arthritis with an earlier onset and a higher incidence than that in IL-17KO-BMT mice. We showed that mice lacking IL-17 BMT rarely developed arthritis and had almost normal joints without cartilage damage or inflammatory cell recruitment, indicating that IL-17 signaling is evidently involved in the induction of arthritis in CIA mice.
T cells are believed to play a critical role in orchestrating the inflammatory response in RA. Thus, suppression of antigen-specific T cell responses is of great importance in RA treatment. Our results show that this protective effect was associated with downregulation of the CII reactive T cell response in the IL-17KO-BMT model. Direct evidence for this beneficial effect is that IL-17 blockade attenuated CIA systemic inflammation in the mice. IL-17 facilitates the production of many inflammatory cytokines and chemokines by activating immune cells (Hwang et al., 2004) . Our results demonstrated that IL-17 deficiency blocks the production of proinflammatory cytokines, including IL-1β, IL-6, and TNF-α, in vitro and in vivo. This may have affected the decreased pSTAT3 protein level. While IL-17 deficiency enhanced IL-10 production by CD4 + T cells and Foxp3 + Tregs, it did not affect IFN-γ-producing CD4 + T cells. IL-10 is a signature cytokine for Tregs, and plays a key role in the control of self-antigen-reactive T cells in vivo (Groux et al., 1997) . We demonstrated that IL-17 blockade inhibited the pathogenic immune reaction and upregulation of IL-10 was involved primarily in the induction of specific T cell tolerance.
Great interest has been focused on understanding the inverse relationship between Th17 cells and Tregs. A balance between Th17 and Tregs is crucial for immune homeostasis. TGF β is required for Th17 and Treg differentiation and it can induce both Foxp3 and RORgt expression (Zhou et al., 2008) . The balance of Th17 cells and Tregs is dependent on the cytokine environment, including IL-6, TGF-β, IL-21, IL-1, and IL-23 levels. One possible explanation suggests that Treg recruitment and proliferation may change the cytokine profile due to the IL-17 deficiency. Tregs play an important role in the prevention of autoimmunity, and they could modulate CIA severity (Bluestone, 2005) . We observed that CD4 + T cells from IL-17 KO-BMT mice show increased differentiation into functional Tregs, which suppressed proliferation of CII-reactive CD4 + T cells (effector) as compared with that in WT-BMT mice. In a co-culture experiment with effector cells, enhanced Tregs inhibited differentiation into IL-17 producing effector T cells, but promoted differentiation into Foxp3 + T cells. IL-17 acts directly on osteoclastogenesis by synergizing with RANKL signaling or driving gene upregulation in osteoblasts, which, in turn, drive osteoclastogenesis (Kotake et al., 1999; Sato et al., 2006) . In the present study, we found that IL-17 deficiency inhibited bone destruction by preventing the formation of osteoclasts and downregulating the expression of osteoclast associated genes, such as TRAP, MMP9, integrin-β3, NFATc1, and cathepsin K. Additionally, we showed that IL-17 blockade induced downregulation of osteoblast-related genes (osteocalcin, Runx2, and RANKL) in the joints and BM. We infer that IL-17 prompt the osteoblasts to osteoclasts differentiation signals, possibly through the induction of RANKL and regulation of gene expression of osteocalcin or Runx2, is an important of bone metastasis on osteoblastic cells. Thus, anti IL-17 therapy produced a powerful therapeutic effect in the treatment of joint destructive arthritis by regulating osteoclastogenesis-associated genes and RANKL expression.
Our results demonstrate that removing IL-17 signaling using a BMT system in a CIA model resulted in marked decreases in arthritis severity. Our observations bear a striking similarity to those reported by other investigators concerning an anti-joint inflammatory role of IL-17. Furthermore, we observed that IL-17 deficiency results in increased functionally suppressive Tregs and reduced levels of other Th17 lineage inflammatory cytokines. In summary, our results support the hypothesis that IL-17 plays a key role in the pathogenesis of inflammatory RA, supporting Il-17 as a therapeutic target in RA.
Methods
Animals
Male DBA/1J (H2-kq), wild-type (WT), and IL-17 -/-on a C57BL/6 (H2-Kb) background mice (Jackson Laboratories, Bar Harbor, ME) were maintained in a specific pathogen-free environment with standard laboratory mouse chow (Ralston Purina, St. Louis, MO). The animals were treated according to the regulations of the Catholic Ethics Committee of the Catholic University of Korea, in conformity with the National Institutes of Health guidelines.
Bone marrow transplantation
Recipient (DBA/1J) mice were exposed to a 1200-cGy dose of radiation from a Mevatron MXE-2 instrument (Siemens, New York, NY) with a focus-to-skin distance of 100 cm and a rate of 200 cGy/min. In total, 1,200 cGy of radiation was administered in a split dose separated by 6 h, and the mice were permitted to rest overnight. The next morning, the donor mice -/-on a C57BL/6 background mice) were sacrificed, and their femurs were removed. Bone marrow was harvested from femurs by flushing three times with phosphate-buffered saline (PBS) supplemented with 1% fetal calf serum (FCS) and filtering the fluid through a cell strainer. Cells were washed in PBS, counted with a hemocytometer, and resuspended at a concentration of 10 7 cells/ml. Tail vein injections of 10 6 donor cells (100 μl) were then administered to each mouse in the recipient group, and the animals were rested for periods ranging from 5 to 12 weeks.
Preparation of CII
Bovine CII was kindly provided by Prof. Andrew Kang of the University of Tennessee. CII was extracted in its native form from fetal calf articular cartilage and purified as described previously (Stuart et al., 1979) .
CIA induction and treatment
CIA was induced after 4 weeks as described previously (Kim et al., 2002) . Briefly, DBA/1J mice were injected in the base of the tail with 100 μg CII emulsified in CFA. Two weeks later, 100 μg CII with Freund's incomplete adjuvant was injected into a hind paw footpad as a booster injection. Clinical signs of arthritis were assessed visually in the wrist and ankle joints, as reported previously (Wooley et al., 1981) .
CIA histological evaluation
A histological analysis was conducted to determine the extent of joint damage. Mouse joint tissues were fixed in 4% paraformaldehyde, decalcified in an EDTA bone decalcifier, and paraffin-embedded. The sections were then dewaxed using xylene and dehydrated through an alcohol series. Endogenous peroxidase activity was quenched with methanol/3% H2O2. Sections were routinely stained with hematoxylin and eosin, safranin-O fast green, and toluidine blue, and were evaluated blindly, as described previously (Camps et al., 2005) .
Immunohistochemistry was performed using the Vectastain ABC kit (Vector Laboratories, Burlingame, CA). Tissues were incubated first with the primary anti-GFP antibody (Abcam Cambridge, MA) overnight at 4 o C, a biotinylated secondary linking Ab, and finally a streptavidin-peroxidase complex for 1 h each. The final color product was developed using AEC chromogen (DAKO, Carpinteria, CA). Sections were counterstained with hematoxylin, and samples were photographed with an Olympus photomicroscope (Tokyo, Japan).
Cell culture
All cell cultures were performed in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 10% FCS, 2 mM glutamine, 100 IU/ml penicillin, 0.1 mg/ml streptomycin, 0.25 μg/ml amphotericin B, and 2 μM β-mercaptoethanol. Spleen or draining lymph node (dLN) cells were cultured with 40 μg/ml CII to observe the T cell response to CII. Treg cultures were supplemented with 5 ng/ml transforming growth factor (TGF)-β (R&D Systems, Minneapolis, MN) and Th17 conditions contained 10 ng/ml IL-6 (Invitrogen), 5 ng/ml TGF-β1 (R&D Systems), 10 μg/ml anti-IL-4, and 10 μg/ml anti IFN γ.
Measurement of cytokines and CII-specific IgG titers
Concentrations of IL-10, IL-17, TNF-α, IL-6, and IL-21 in cell culture supernatants and serum were measured using a sandwich enzyme-linked immunosorbent assay (ELISA; Duoset; R&D Systems, Lille, France). Serum levels of anti-CII IgG, IgG1, and IgG2a antibodies were measured using a commercially available ELISA kit (Bethyl Laboratories, Montgomery, TX).
Proliferation assay
Cells were pulsed with 1 μCi 3 H-thymidine (GE Healthcare, Piscataway, NJ) per well for the final 8 h of the 72-h culture period. Finally, 3 H-thymidine incorporation was determined using a liquid scintillation counter (Beckman. Fullerton, CA).
Flow cytometric analysis
Mononuclear cells were immunostained with various combinations of the following fluorescence-conjugated antibodies: CD25, CD4, CCR7, Foxp3, IL-17, cytotoxic T lymphocyte antigen-4 (CTLA-4), and glucocorticoid-induced tumor necrosis factor family receptor. These cells were also intracellularly stained with the following antibodies: CTLA-4 (BD Biosciences, Sparks, MD), IL-17, and Foxp3 (eBioscience San Diego, CA). Before intracellular staining, cells were restimulated for 4 h with 25 ng/ml phorbol myristic acid and 250 ng/ml ionomycin in the presence of GolgiSTOP (BD Biosciences). Intracellular staining was conducted using an intracellular staining kit (eBioscience), according to the manufacturer's protocol. Flow cytometric analysis was performed on a FACSCalibur cytometer (BD Biosciences).
Carboxylfluorescein succinimidyl ester (CFSE) labeling
Mononuclear cells isolated from mouse spleens were washed once in 0.1% bovine serum albumin (BSA) in PBS and labeled with 1 μl 5 mM CFSE (Invitrogen, Carlsbad, CA) at a density of 1 × 10 7 cells/ml in 0.1% BSA in PBS for 10 min at 37 o C in the dark. CFSE labeled cells were stimulated with anti-CD3 monoclonal antibody (1 μg/ml) and CII (40 μg/ml) for 3 days in 24-well plates (1 × 10 6 /ml). Flow cytometry was used to assess CFSE fluorescence.
Real-time reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted using the Trizol-LS reagent (Invitrogen). Total RNA (2 μg) was reverse transcribed at 50 o C for 2 min, followed by 60 o C for 30 min. Quantitative PCR was performed using the FastStart DNA Master SYBR Green I kit and a LightCycler 480 Detection system (Roche, Meylan, France), as specified by the manufacturer. The crossing point (Cp) was defined as the maximum of the second derivative from the fluorescence curve. Negative controls were included and contained all elements of the reaction mixture except for template DNA. For quantitation, we report relative mRNA expression levels of specific genes obtained using the 2 -ΔCt method and used the β-actin housekeeping gene for normalization. The following gene-specific primers were used: tartrate-resistant acid phosphatase (TRAP) (forward: 5'-TCCTGGCTCAAAAAGC AGT-3'; reverse: 5'-ACATAGCCCACACCGTTCTC-3'), NFATc1 (forward: 5'-CGGGAAGAAGATGGTGCTGT-3'; reverse: 5'-TTGGACGGGGCTGGTTAT-3'), MMP9 (forward: 5'-CTG TCCAGACCAAGGGTACAGCCT-3'; reverse: 5'-GAGGTAT AGTGGGACACATAGTGG-3'), CTR (forward: 5'-CGGACT TTGACACAGCAGAA-3'; reverse: 5'-AGCAGCAATCGAC GAGT-3'), integrin-β (forward: 5'-CTGTGGGCTTTAAGCA GC-3'; reverse: 5'-GAGGGTCGGTAATCCTCCTC-3'), cathepsin K (forward: 5'-CAGCAGAGGTGTGTACTATG-3'; reverse: 5'-GCGTTGTTCTTATTCCGAGC-3'), oscar (forward: 5'-CCTAGCCTCATACCCCCAG-3'; reverse: 5'-CAAACCG CCAGGCAGATTG-3'), RANKL (forward: 5'-TGTACTTTCG AGCGCAGATG-3'; reverse: 5'-CCACAATGTGTTGCAGTT CC-3'), osteocalcin (forward: 5'-CTGACCTCACAGATGCC AAGC-3'; reverse: 5'-TGGTCTGATAGCTCGTCACTTG-3'), runx2 (forward: 5'-TGTTCTCTGATCGCCTCAGTG-3'; reverse: 5'-AATGGGATCTGTAATCTGACTCT-3') and β-actin (forward: 5'-GAAATCGTGCGTGACATCAAAG-3'; reverse: 5'-TGTA GTTTCATGGATGCCACAG-3').
Statistical analysis
Data are presented as means ± standard deviations (SDs). Statistical analyses were performed using the SPSS software (ver. 10.0 for Windows; SPSS, Chicago, IL). The intergroup analysis was performed using a Mann-Whitney U-test. P-values ＜ 0.05 were considered to indicate statistical significance.
